在美国林业发展局发出警告后, 中国禁止Sun Pharma的阿尔茨海默氏病药物超过制造缺陷。 China bans Sun Pharma’s Alzheimer’s drug over manufacturing flaws, following U.S. FDA warning.

中国禁止进口、销售和使用太阳制药工业用于治疗阿尔茨海默氏病相关痴呆症的Rivistigmine氢硝酸盐胶囊,因为经过远程检查发现印度制药厂的污染预防和质量管理存在缺陷。 China has banned the import, sale, and use of Sun Pharmaceutical Industries’ rivastigmine hydrogen tartrate capsules, used to treat Alzheimer’s-related dementia, after a remote inspection revealed deficiencies in contamination prevention and quality management at the drug’s Indian manufacturing facility. 美国FDA在2024年就类似的制造违规行为发出警告后采取了这一举措. The move follows a 2024 U.S. FDA warning over similar manufacturing violations. 印度收入最大的制药商Sun Pharma没有发表评论。 Sun Pharma, India’s largest drugmaker by revenue, has not commented. 没有证实存在更广泛的安全风险。 No broader safety risks have been confirmed.